Sarah M Temkin1, Gini Fleming. 1. Department of Obstetrics/Gynecology, The University of Chicago, Chicago, IL 60637, USA. stemkin@babies.bsd.uchicago.edu
Abstract
BACKGROUND: Endometrial cancer is the most common gynecologic malignancy. The majority of patients have disease confined to the uterus and have an excellent overall prognosis. However, subgroups of patients have advanced primary disease or recurrences following primary treatment. METHODS: The management of metastatic disease is variable, depending on factors such as comorbidities, tumor grade, performance status, and prior treatments. Management options include hormonal therapy and cytotoxic chemotherapy, as well as targeted therapies that inhibit angiogenesis and the cellular signaling pathways involved in cell growth and proliferation. A comprehensive review of these treatments for metastatic endometrial cancer was conducted and is discussed. RESULTS: Hormonal therapy and cytotoxic chemotherapy have traditionally been used in the treatment of metastatic endometrial cancer. Advances in molecular biology have led to multiple potential targeted therapies to be used in the treatment of metastatic endometrial cancer. CONCLUSIONS: While several treatment modalities are now available to treat patients who present with metastatic endometrial cancer, overall prognosis remains poor.
BACKGROUND:Endometrial cancer is the most common gynecologic malignancy. The majority of patients have disease confined to the uterus and have an excellent overall prognosis. However, subgroups of patients have advanced primary disease or recurrences following primary treatment. METHODS: The management of metastatic disease is variable, depending on factors such as comorbidities, tumor grade, performance status, and prior treatments. Management options include hormonal therapy and cytotoxic chemotherapy, as well as targeted therapies that inhibit angiogenesis and the cellular signaling pathways involved in cell growth and proliferation. A comprehensive review of these treatments for metastatic endometrial cancer was conducted and is discussed. RESULTS: Hormonal therapy and cytotoxic chemotherapy have traditionally been used in the treatment of metastatic endometrial cancer. Advances in molecular biology have led to multiple potential targeted therapies to be used in the treatment of metastatic endometrial cancer. CONCLUSIONS: While several treatment modalities are now available to treat patients who present with metastatic endometrial cancer, overall prognosis remains poor.
Authors: Kimberly K Leslie; Kristina W Thiel; Michael J Goodheart; Koen De Geest; Yichen Jia; Shujie Yang Journal: Obstet Gynecol Clin North Am Date: 2012-06 Impact factor: 2.844
Authors: Tobias S Schiergens; Juliane Lüning; Bernhard W Renz; Michael Thomas; Sebastian Pratschke; Hao Feng; Serene M L Lee; Jutta Engel; Markus Rentsch; Markus Guba; Jens Werner; Wolfgang E Thasler Journal: J Gastrointest Surg Date: 2016-02-26 Impact factor: 3.452
Authors: Yan Huang; Wei Hu; Jie Huang; Fangrong Shen; Yunjie Sun; Cristina Ivan; Sunila Pradeep; Robert Dood; Monika Haemmerle; Dahai Jiang; Lingegowda S Mangala; Kyunghee Noh; Jean M Hansen; Heather J Dalton; Rebecca A Previs; Archana S Nagaraja; Michael McGuire; Nicholas B Jennings; Russell Broaddus; Robert L Coleman; Anil K Sood Journal: Mol Cancer Ther Date: 2017-12-13 Impact factor: 6.261